Css LLC Altimmune, Inc. Transaction History

Css LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $219,225 - $460,435	20,546 New	20,546 $262,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $295,665 - $589,577	-35,073 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $4,925 - $8,230	500 Added 1.45%	35,073 $345,000
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $341,555 - $653,282	26,873 Added 349.0%	34,573 $489,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $21,168 - $38,394	2,700 Added 54.0%	7,700 $87,000
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $49,650 - $166,300	5,000 New	5,000 $66,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $428M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.